Skip to main content
SpringerLink
Log in

Neuromyelitis optica: Diagnosis, pathogenesis, and treatment

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Although the co-occurrence of myelitis and optic neuritis that characterizes neuromyelitis optica (NMO) was recognized over a century ago, distinguishing NMO from multiple sclerosis relied solely on clinical criteria until recently. The identification of a biomarker that has high specificity for NMO is clinically useful for distinguishing NMO from multiple sclerosis and identifying patients at high risk for recurrent myelitis and optic neuritis. That fact that the biomarker is an autoantibody that recognizes aquaporin 4 (AQP4), a water channel expressed on astrocyte podocytes, has substantially contributed to the hypothesis that NMO is a humorally mediated autoimmune disease. This review discusses the discovery of the NMO-IgG biomarker, the identification of AQP4 as its target, the clinical applications of these advances, the pathologic implications for the anti-AQP4 antibody, and advances in NMO treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Lennon VA, Wingerchuk DM, Kryzer TJ, et al.: A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106–2112.

    Article  PubMed  CAS  Google Scholar 

  2. Agre P, Nielsen S: The aquaporin family of water channels in kidney. Nephrologie 1996, 17:409–415.

    PubMed  CAS  Google Scholar 

  3. Tait MJ, Saadoun S, Bell BA, et al.: Water movements in the brain: role of aquaporins. Trends Neurosci 2008, 31:37–43.

    Article  PubMed  CAS  Google Scholar 

  4. Amiry-Moghaddam M, Frydenlund DS, Ottersen OP: Anchoring of aquaporin-4 in brain: molecular mechanisms and implications for the physiology and pathophysiology of water transport. Neuroscience 2004, 129:999–1010.

    PubMed  CAS  Google Scholar 

  5. Lennon VA, Kryzer TJ, Pittock SJ, et al.: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473–477.

    Article  PubMed  CAS  Google Scholar 

  6. Takahashi T, Fujihara K, Nakashima I, et al.: Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med 2006, 210:307–313.

    Article  PubMed  CAS  Google Scholar 

  7. Paul F, Jarius S, Aktas O, et al.: Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 2007, 4:e133

    Article  PubMed  Google Scholar 

  8. Marignier R, De Seze J, Vukusic S, et al.: NMO-IgG and Devic’s neuromyelitis optica: a French experience. Mult Scler 2008 (in press).

  9. Cree BA, Goodin DS, Hauser SL: Neuromyelitis optica. Semin Neurol 2002, 22:105–122.

    Article  PubMed  Google Scholar 

  10. Wingerchuk DM, Hogancamp WF, O’Brien PC, et al.: The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999, 53:1107–1114.

    PubMed  CAS  Google Scholar 

  11. Wingerchuk DM, Lennon VA, Pittock SJ, et al.: Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485–1489.

    Article  PubMed  CAS  Google Scholar 

  12. Saiz A, Zuliani L, Blanco Y, et al.: Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol 2007, 254:1233–1237.

    Article  PubMed  Google Scholar 

  13. Weinshenker BG, Wingerchuk DM, Vukusic S, et al.: Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006, 59:566–569.

    Article  PubMed  CAS  Google Scholar 

  14. Mateillo M, Lennon VA, Jacob A, et al.: NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008 (in press).

  15. Dinkin MJ, Cestari DM, Stein MC, et al.: NMO antibody-positive recurrent optic neuritis without clear evidence of transverse myelitis. Arch Ophthalmol 2008, 126:566–570.

    Article  PubMed  Google Scholar 

  16. Takahashi T, Fujiara K, Nakashima I, et al.: Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007, 130:1235–1243.

    Article  PubMed  Google Scholar 

  17. Misu T, Fujihara K, Nakamura M, et al.: Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report. Tohoku J Exp Med 2006, 209:269–275.

    Article  PubMed  Google Scholar 

  18. Lucchinetti CF, Mandler RN, McGavern D, et al.: A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 2002, 125:1450–1461.

    Article  PubMed  Google Scholar 

  19. Roemer SF, Parisi JE, Lennon VA, et al.: Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007, 130:1194–1205.

    Article  PubMed  Google Scholar 

  20. Misu T, Fujihara K, Nakashima I, et al.: Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005, 65:1479–1482.

    Article  PubMed  CAS  Google Scholar 

  21. Misu T, Fujihara K, Kakita A, et al.: Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007, 130:1224–1234.

    Article  PubMed  CAS  Google Scholar 

  22. Sinclair C, Kirk J, Herron B, et al.: Absence of aquaporin-4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-appearing white matter. Acta Neuropathol 2007, 113:187–194.

    Article  PubMed  CAS  Google Scholar 

  23. Hinson SR, Pittock SJ, Lucchinetti CF, et al.: Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007, 69:2221–2231.

    Article  PubMed  CAS  Google Scholar 

  24. Zeng XN, Sun XL, Gao L, et al.: Aquaporin-4 deficiency down-regulates glutamate uptake and GLT-1 expression in astrocytes. Mol Cell Neurosci 2007, 34:34–39.

    Article  PubMed  CAS  Google Scholar 

  25. Pittock SJ, Lennon VA, Krecke K, et al.: Brain abnormalities in neuromyelitis optica. Arch Neurol 2006, 63:390–396.

    Article  PubMed  Google Scholar 

  26. Pittock SJ, Weinshenker BG, Lucchinetti CF, et al.: Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006, 63:964–968.

    Article  PubMed  Google Scholar 

  27. Kira J, Harada M, Yamaguchi Y, et al.: Hyperprolactinemia in multiple sclerosis. J Neurol Sci 1991, 102:61–66.

    Article  PubMed  CAS  Google Scholar 

  28. Vernant JC, Cabre P, Smadja D, et al.: Recurrent optic neuromyelitis with endocrinopathies: a new syndrome. Neurology 1997, 48:58–64.

    PubMed  CAS  Google Scholar 

  29. Yamasaki K, Horiuchi I, Minohara M, et al.: Hyperprolactinemia in optico-spinal multiple sclerosis. Intern Med 2000, 39:296–299.

    Article  PubMed  CAS  Google Scholar 

  30. Poppe AY, Lapierre Y, Melancon D, et al.: Neuromyelitis optica with hypothalamic involvement. Mult Scler 2005, 11:617–621.

    Article  PubMed  Google Scholar 

  31. Cabrera-Gomez J, Saiz-Hinarejos A, Graus F, et al.: Brain magnetic resonance imaging findings in acute relapses of neuromyelitis optica spectrum disorders. Mult Scler 2008, 14:248–251.

    Article  PubMed  Google Scholar 

  32. Levy M, Jones M, Kerr D: The role of anti-aquaporin-4 antibodies in the pathogenesis of neuromyelitis opica [abstract P04.061]. Paper presented at the 59th American Academy of Neurology Annual Meeting. Boston, MA. April 28 to May 5, 2007.

  33. Lalive PH, Menge T, Barman I, et al.: Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays. Neurology 2006, 67:176–177.

    Article  PubMed  CAS  Google Scholar 

  34. Weinshenker BG, O’Brien PC, Petterson TM, et al.: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999, 46:878–886.

    Article  PubMed  CAS  Google Scholar 

  35. Keegan M, Pineda AA, McClelland RL, et al.: Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002, 58:143–146.

    Article  PubMed  CAS  Google Scholar 

  36. Watanabe S, Naashima I, Misu T, et al.: Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007, 13:128–132.

    Article  PubMed  CAS  Google Scholar 

  37. Aguilera AJ, Carlow TJ, Smith KJ, et al.: Lymphocytaplasmapheresis in Devic’s syndrome. Transfusion 1985, 25:54–56.

    Article  PubMed  CAS  Google Scholar 

  38. Nozaki I, Hamaguchi T, Komai K, et al.: Fulminant Devic disease successfully treated by lymphocytapheresis. J Neurol Neurosurg Psychiatry 2006, 77:1094–1095.

    Article  PubMed  CAS  Google Scholar 

  39. Wingerchuk DM, Pittock SJ, Lucchinetti CF, et al.: A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007, 68:603–605.

    Article  PubMed  CAS  Google Scholar 

  40. Papeix C, Vidal JS, De Seze J, et al.: Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007, 13:256–259.

    Article  PubMed  CAS  Google Scholar 

  41. Warabi Y, Matsumoto Y, Hayashi H: Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 2007, 252:57–61.

    Article  PubMed  CAS  Google Scholar 

  42. Mandler RN, Ahmed W, Dencoff JE: Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998, 51:1219–1220.

    PubMed  CAS  Google Scholar 

  43. Cree BA, Lamb S, Morgan K, et al.: An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005, 64:1270–1272.

    PubMed  CAS  Google Scholar 

  44. Jacobs A, Weinshenker B, McKinskey N, et al.: Retrospective analysis of rituximab treatment of 26 cases of neuromyelitis optica [abstract S32.002]. Paper presented at the 59th American Academy of Neurology Annual Meeting. Boston, MA. April 28 to May 5, 2007.

  45. Genain C, Kornyeyva E, Ross M, et al.: An open label clinical trial of rituximab in neuromyeltis optica [abstract S52.004]. Paper presented at the 59th American Academy of Neurology Annual Meeting. Boston, MA. April 28 to May 5, 2007.

  46. Capobinaco M, Malucchi S, Di Sapio A, et al.: Variable responses to rituximab treatment in neuromyelitis optica (Devic’s disease). Neurol Sci 2007, 28:209–211.

    Article  Google Scholar 

  47. Weinstock-Guttman B, Ramanathan M, Lincoff N, et al.: Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006, 63:957–963.

    Article  PubMed  Google Scholar 

  48. Watanabe S, Misu T, Miyazama I, et al.: Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 2007, 13:968–974.

    Article  PubMed  CAS  Google Scholar 

  49. Bakker J, Metz L: Devic’s neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 2004, 31:265–267.

    PubMed  Google Scholar 

  50. Okada K, Tsuji S, Tanaka K: Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern Med 2007, 46:1671–1672.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Multiple Sclerosis Center, University of California San Francisco, 350 Parnassus Avenue, Suite 908, San Francisco, CA, 94117, USA

    Bruce Cree

Authors
  1. Bruce Cree
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruce Cree.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cree, B. Neuromyelitis optica: Diagnosis, pathogenesis, and treatment. Curr Neurol Neurosci Rep 8, 427–433 (2008). https://doi.org/10.1007/s11910-008-0066-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-008-0066-2

Keywords

Search

Navigation